Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.180 -0.060 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
Via MarketMinute
Topics Intellectual Property Workforce
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Is there a glimmer of hope for either of these underperforming healthcare companies? 
Via The Motley Fool
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
Via Stocktwits
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
Investors have certainly seen explosive gains from shares of biopharma companies in similar situations. 
Via The Motley Fool
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Can This Beaten-Down Stock Bounce Back?
This biotech company is innovative, but the market demands more than that. 
Via The Motley Fool
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Got Mashed on Monday
The company announced a flotation of its common shares that is potentially quite dilutive. 
Via The Motley Fool
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
 
Via Benzinga
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
Time is running out for the company to mount a comeback. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Iovance Biotherapeutics Stock Was Climbing Today
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
Via The Motley Fool
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Plummeted Today
The company's top line nearly doubled. 
Via The Motley Fool
What 7 Analyst Ratings Have To Say About Iovance Biotherapeutics
 
Via Benzinga
Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session
 
Via Benzinga
Which stocks are moving before the opening bell on Friday?
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening
Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales. 
Via Benzinga
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.